[File, Standard]There is a silver lining in the fight against the Covid-19 pandemic after Johnson & Johnson Company moved to seek approval of emergency use for a single-dose vaccine. The Covid-19 vaccine candidate (JNJ-78436735) developed by Janssen Pharmaceutical Companies of Johnson & Johnson, is at Phase 3 of the clinical trial. Appropriate timingAccording to Johnson & Johnson, the timing for approval of the vaccine is appropriate. “The Company anticipates announcing top-line Phase 3 data for its single-dose Janssen Covid-19 vaccine candidate in late January 2021,” reads a statement published on the Johnson & Johnson website on Tuesday. S supported further development of the Johnson & Johnson vaccine.

Source: Standard Digital January 27, 2021 19:46 UTC